Table 2 Characteristics of CHD patients by coronary stenosis severity.

From: Circulating Hematopoietic Stem/Progenitor Cells are Associated with Coronary Stenoses in Patients with Coronary Heart Disease

Characteristic

Coronary artery stenoses

mild

medium

severe

Number in category

41

132

141

Number of subjects (%)

Women

18 (43.9)

46 (34.8)

48 (34.0)

Smokers

12 (29.3)

77 (58.3)

76 (53.9)

Drinking alcohol

11 (26.8)

44 (33.3)

41 (29.1)

Hypertension

28 (68.3)

84 (63.6)

94 (66.7)

Antihypertensive treatment

34 (82.9)

99 (75.0)

114 (80.9)

Dyslipidemia

113 (73.4)

106 (80.3)

115 (81.6)

Statins treatment

33 (80.5)

114 (86.4)

119 (84.4)

Diabetes mellitus

19 (46.3)

26 (19.7)

51 (36.2)

Myocardial infarction

3 (13.1)

24 (42.9)

29 (51.8)

Mean (SD) of characteristic

Age (years)

62.0 (8.2)

59.6 (10.5)

63.0 (11.1)

Systolic pressure (mm Hg)

138.8 (16.9)

134.4 (19.5)

134.3 (16.8)

Diastolic pressure (mm Hg)

80.9 (11.0)

80.1 (13.0)

79.3 (11.9)

Mean arterial pressure (mm Hg)

100.2 (11.8)

98.2 (13.5)

97.6 (11.9)

Heart rate (beats per minute)

76.0 (12.5)

74.8 (14.4)

74.5 (11.2)

Biochemical data

Serum creatinine (μmol/L)

71 (59–76)

72 (63–83)

78 (66–88)†

eGFR (mL/min/1.73 m2)

90.8 (13.1)

90.2 (16.1)

83.9 (17.6)†

Serum triglyceride (mmol/L)

1.58 (0.92–2.12)

1.57 (1.12–2.18)

1.48 (0.99–1.92)

Total cholesterol (mmol/L)

3.98 (0.76)

4.46 (0.93)†

4.40 (1.13)†

LDL cholesterol (mmol/L)

2.48 (0.70)

2.88 (0.78)†

2.85 (0.98)*

HDL cholesterol (mmol/L)

1.00 (0.22)

1.08 (0.27)

1.03 (0.20)

Fasting blood glucose (mmol/L)

6.74 (2.34)

6.12 (2.46)

6.74 (3.35)

γ-glutamyltransferase (units/L)

21 (15–31)

26 (20–37)

22 (16–32)

uric acid (μmol/L)

304.5 (84.5)

327.4 (82.6)

344.1 (91.2)*

Apolipoprotein A-I (μg/mL)

8.90 (1.85)

8.65 (2.01)

8.97 (2.11)

Apolipoprotein B (μg/mL)

200.9 (45.3)

200.0 (51.7)

204.2 (50.1)

Inflammation markers

HSPC (%)

0.04 (0.03–0.09)

0.07 (0.03–0.13)†

0.07 (0.04–0.14)§

C-reactive protein (mg/L)

1.10 (0.79–2.98)

1.56 (0.90–4.59)

1.90 (0.90–6.20)*

GM-CSF (ng/L)

105.5 (21.7)

107.6 (21.9)

109.7 (22.7)

SDF-1α (pg/mL)

3530.7 (612.6)

3553.9 (657.1)

3579.3 (653.6)

WBC count (x109/L)

6.85 (1.91)

7.97 (2.83)†

7.68 (2.72)

Neutrophils (x109/L)

4.38 (1.51)

5.35 (2.56)†

5.15 (2.52)*

Monocytes (x109/L)

0.48 (0.22)

0.50 (0.20)

0.50 (0.19)

Lymphocytes (x109/L)

1.77 (0.54)

1.92 (0.89)

1.83 (0.71)

Coagulation markers

Fibrinogen (g/L)

2.93 (2.42–3.26)

3.13 (2.73–3.57)

3.20 (2.69–3.70)

D-dimer (mg/L)

0.11 (0.07–0.16)

0.10 (0.06–0.16)

0.11 (0.07–0.19)

Circulating HSPCs (%)

0.06 (0.02–0.07)

0.10 (0.03–0.13)*

0.11 (0.04–0.14)

  1. The extent of CHD was defined by the number of significant coronary artery stenoses. Myocardial infarction included both ST-elevated and non-ST-elevated myocardial infarction. eGFR: estimated glomerular filtration rate. HSPCs: hematopoietic stem/progenitor cells. Logarithmically transformed values are expressed as geometric means (interquartile range). Means were compared using t-test and ANOVA and proportions by Fisher’s exact test. Significance of the difference when compared with the mild group: *P ≤ 0.05; †P ≤ 0.01.
Back to article page